Americas Insomnia Market Overview
The Americas Insomnia Market Size was valued at USD 2.28 Billion in 2023. The Global Americas Insomnia industry is projected to grow from USD 2.43 Billion in 2024 to USD 3.73 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.9% during the forecast period (2024 - 2032). Insomnia is disorder related to sleep, it creates difficulty in sleeping. The symptoms show dissatisfaction with sleep, fatigue, low energy, less concentration, low performance, irritation, change in moods and many more. There are three types of insomnia that is transient, acute and chronic. The transient insomnia is sleeping disorder that occurs for few days or few weeks. The acute insomnia may be experience when students have exams or a person has an interview. This is a short time difficulty in sleep that lasts for some weeks. While the chronic insomnia is long term disorder of sleep seen in people having regular shift timings on their jobs, unhealthy sleeping habits, clinical disorders and some other psychiatric issues or health issues and many more reasons associated. The prevalence rate of insomnia is very high and is increasing day by day. Worldwide millions of people are getting affected by the sleeping disorder. According to the CDC study, it says that American do sleep for 7hrs and 36min in working days while 40min more on non-working days. The insomnia is majorly seen in American women, data says that 24 percent of women have woken up with no well rest, while the 16 percent of men have experienced same. This percentage is very less in contrast to people who suffers from insomnia.
Study Objectives Americas Insomnia Market Research Report
- To provide the Detail Overview of American insomnia market.
- To provide In-depth market segmentation and sub segmentations.
- To provide insights about factors affecting the market growth
- To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
- To provide Competitive landscape and key players in the market.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to geography and countries- North America and South America.
- To provide country level analysis of the market with respect to the current market size and future prospective
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Americas Insomnia Market.
Key Players for Americas Insomnia Market
The number of local and global level players working for the insomnia are: Eisai, Co. (Japan), Pfizer, Inc. (US), Merck & Co Inc (US), Sanofi (France), Takeda Pharmaceutical Company (Japan), Meda Consumer Healthcare Inc (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Flynn Pharma (UK), Johnson & Johnson (US), Astellas (UK), Biocodex S A (France), Neurim (Switzerland), SkyePharma (UK), and Vanda Pharmaceuticals Inc. (US).
Segmentation
The Americas insomnia market is segmented on the basis of, types of therapy, drug formulation and by type of disease. On the basis of types of therapy market is segmented into pharmacological therapy and non-pharmacological therapy. On the basis of the pharmacological therapy is sub-segmented into Benzodiazepines, Non-benzodiazepines, Melatonin receptor agonists and others. Likewise on the basis of the non-pharmacological therapy is also sub-segmented into Relaxation therapy, Cognitive behavioural therapy, Sleep hygiene education, Stimulus Controls, Paradoxical intension and others. On the basis of drug formulation the drugs are being formulated in capsules, tablets and others. Whereas on the basis of type of disease it includes poor quality of sleep, sleep maintenance and others.
Regional Analysis
On regional basis the Americas insomnia market is segmented into two regions- North America and South America. Further North America is segmented into US and Canada. The North America region is experiencing more number of cases for insomnia. The cases are seen with unintentionally falling asleep and nodding while driving. The sleep related disorders are also seen because of the hypertension, cardio problems, cancer, depression, obesity and many more. It is estimated that near about 70 million US citizens are affected by insomnia.
The report for Americas Insomnia Market Research Report of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
Intended Audience
- Manufacturing and packaging industries.
- Insomnia devices and drug manufacturers
- Biotechnology Companies
- Bio-Pharmaceutical Companies
- Research and Development (R&D) Companies
- Government Research Laboratories
- Medical Research Institutes
Report Attribute/Metric
|
Details
|
Market Size 2023
|
USD 2.28Â billion
|
Market Size 2024
|
USD 2.43 billion
|
Market Size 2032
|
USD 3.73 billion
|
Compound Annual Growth Rate (CAGR)
|
4.9 % (2024-2032)
|
Base Year
|
2023
|
Market Forecast Period
|
2024-2032
|
Historical Data
|
2019- 2021
|
Market Forecast Units
|
Value (USD Billion)
|
Report Coverage
|
Revenue Forecast, Growth Factors, Market Competitive Landscape, and Trends
|
Segments Covered
|
Types Of Therapy, Drug Formulation, Type Of Diseases Condition and Region
|
Geographies Covered
|
North America
|
Countries Covered
|
U.S, Canada
|
Key Companies Profiled
|
Eisai, Co. (Japan), Pfizer, Inc. (US), Merck & Co Inc (US), Sanofi (France), Takeda Pharmaceutical Company (Japan), Meda Consumer Healthcare Inc (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Flynn Pharma (UK), Johnson & Johnson (US), Astellas (UK), Biocodex S A (France), Neurim (Switzerland), SkyePharma (UK), and Vanda Pharmaceuticals Inc. (US).Â
|
Key Market Opportunities
|
Increasing awareness of sleep disorders, and changing lifestyle patterns
|
Key Market Dynamics
|
Increasing prevalence of insomnia among the population
|
Americas Insomnia Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report